our team


Andréa C. LeBlanc, Ph.D.

Founder , President & Interim CEO
  • Head of successful academic laboratory for >30 yrs
  • Exposure to pharmaceutical companies through collaborations (Merck, Pfizer, Neurochem Inc)
  • Certificat d’accomplissement au Programme Québecois d’Entrepreneuriat Scientifique (QcES) Studio V1

Louise R. Guerrette, B.Sc. Adm., LLB

Vice-President & General Counsel
  • Legal Counsel for Alis Technologies Inc. (1997), Assistant Corporate Secretary for Transat A.T. (2005)
  • President Lex Scripta Inc. (2008): focus on business legal counsel

Philippe Lièvre, B.Sc (Pharm), MBA

Acting Chief Business Development
  • Business Development & Established Medicines (2014-2017) for Novartis Pharma K.K. (Tokyo)
  • Head of Pharma Alliance management (2018-2021) for Novartis A.D. (Basel)
  • Chief Business Officer and Co-Founder of start-up Priothera (currently in clinical trial phase 2b/3)


Andréa C. LeBlanc, Ph.D.

Chief Scientific Officer
  • Committed to finding a cure for cognitive impairment
  • > 32 yrs research on neurodegeneration
  • Spearheaded research on caspases and cognition
  • Discovered Nlrp1-Casp1-Casp6 neuro-degenerative pathway

Joseph Flores, Ph.D.

Senior Research Scientist
  • Conducted pre-clinical research with VX-765
  • Expertise on testing memory in mice
  • Expertise in assessing neurode-generative features in brain
  • Expertise in assisting academia and industry with pre-clinical research in neurodegenerative diseases
  • 8 years of experience on this project

François-Xavier Lacasse, Ph.D.

Consultant in Drug Development
  • Seasoned executive 
  • Specialized in drug development
  • In-depth experience and scientific expertise with regulatory agencies (Health Canada, EMA and FDA) 
  • 24 years of experience in the pharmaceutical industry. 

Marie-Lyne Fillion, M.Sc.

Research Associate
  • Expertise in mouse husbandry, genetics,  biochemistry, cell biology, and molecular biology techniques
  • 6 yrs in LeBlanc lab as research assistant/lab manager